Literature DB >> 31353426

Debate on Insulin vs Non-insulin Use in the Hospital Setting-Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?

Francisco J Pasquel1, Maya Fayfman1, Guillermo E Umpierrez2.   

Abstract

PURPOSE OF REVIEW: Hyperglycemia contributes to a significant increase in morbidity, mortality, and healthcare costs in the hospital. Professional associations recommend insulin as the mainstay of diabetes therapy in the inpatient setting. The standard of care basal-bolus insulin regimen is a labor-intensive approach associated with a significant risk of iatrogenic hypoglycemia. This review summarizes recent evidence from observational studies and clinical trials suggesting that not all patients require treatment with complex insulin regimens. RECENT
FINDINGS: Evidence from clinical trials shows that incretin-based agents are effective in appropriately selected hospitalized patients and may be a safe alternative to complicated insulin regimens. Observational studies also show that older agents (i.e., metformin and sulfonylureas) are commonly used in the hospital, but there are few carefully designed studies addressing their efficacy. Therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors, alone or in combination with basal insulin, may effectively control glucose levels in patients with mild to moderate hyperglycemia. Further studies with glucagon-like peptide-1 (GLP-1) receptor analogs and older oral agents are needed to confirm their safety in the hospital.

Entities:  

Keywords:  DPP-4 inhibitors; Diabetes; Hospitalized patients; Incretin; Inpatient; Insulin

Mesh:

Substances:

Year:  2019        PMID: 31353426     DOI: 10.1007/s11892-019-1184-8

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  87 in total

1.  Intensive insulin therapy in critically ill patients.

Authors:  G van den Berghe; P Wouters; F Weekers; C Verwaest; F Bruyninckx; M Schetz; D Vlasselaers; P Ferdinande; P Lauwers; R Bouillon
Journal:  N Engl J Med       Date:  2001-11-08       Impact factor: 91.245

Review 2.  Management of diabetes and hyperglycemia in hospitals.

Authors:  Stephen Clement; Susan S Braithwaite; Michelle F Magee; Andrew Ahmann; Elizabeth P Smith; Rebecca G Schafer; Irl B Hirsch; Irl B Hirsh
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

3.  Retrospective review of metformin in inpatients and outpatients at the University of Michigan.

Authors:  Hanady M Sharabash; Tami L Remington; Peter Mar; Ralph Winston; Paul C Walker
Journal:  Diabetes Care       Date:  2006-01       Impact factor: 19.112

4.  Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.

Authors:  George G Sokos; Lazaros A Nikolaidis; Sunil Mankad; Dariush Elahi; Richard P Shannon
Journal:  J Card Fail       Date:  2006-12       Impact factor: 5.712

5.  Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes.

Authors:  Guillermo E Umpierrez; Scott D Isaacs; Niloofar Bazargan; Xiangdong You; Leonard M Thaler; Abbas E Kitabchi
Journal:  J Clin Endocrinol Metab       Date:  2002-03       Impact factor: 5.958

6.  Effects of thiazolidinediones on stroke recovery: a case-matched controlled study.

Authors:  Jongmin Lee; Michael Reding
Journal:  Neurochem Res       Date:  2006-09-08       Impact factor: 3.996

7.  Glucose control and mortality in critically ill patients.

Authors:  Simon J Finney; Cornelia Zekveld; Andi Elia; Timothy W Evans
Journal:  JAMA       Date:  2003-10-15       Impact factor: 56.272

8.  Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

Authors:  Thomas Nyström; Mark K Gutniak; Qimin Zhang; Fan Zhang; Jens Juul Holst; Bo Ahrén; Ake Sjöholm
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-09-07       Impact factor: 4.310

9.  Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial).

Authors:  Guillermo E Umpierrez; Dawn Smiley; Ariel Zisman; Luz M Prieto; Andres Palacio; Miguel Ceron; Alvaro Puig; Roberto Mejia
Journal:  Diabetes Care       Date:  2007-05-18       Impact factor: 19.112

10.  Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.

Authors:  Lazaros A Nikolaidis; Sunil Mankad; George G Sokos; Glen Miske; Ankur Shah; Dariush Elahi; Richard P Shannon
Journal:  Circulation       Date:  2004-02-23       Impact factor: 29.690

View more
  7 in total

1.  A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial.

Authors:  Francisco J Pasquel; M Cecilia Lansang; Ameer Khowaja; M Agustina Urrutia; Saumeth Cardona; Bonnie Albury; Rodolfo J Galindo; Maya Fayfman; Georgia Davis; Alexandra Migdal; Priyathama Vellanki; Limin Peng; Guillermo E Umpierrez
Journal:  Diabetes Care       Date:  2020-04-09       Impact factor: 19.112

2.  Implementation of Continuous Glucose Monitoring in the Hospital: Emergent Considerations for Remote Glucose Monitoring During the COVID-19 Pandemic.

Authors:  Rodolfo J Galindo; Grazia Aleppo; David C Klonoff; Elias K Spanakis; Shivani Agarwal; Priya Vellanki; Darin E Olson; Guillermo E Umpierrez; Georgia M Davis; Francisco J Pasquel
Journal:  J Diabetes Sci Technol       Date:  2020-06-14

3.  Individualizing Inpatient Diabetes Management During the Coronavirus Disease 2019 Pandemic.

Authors:  Francisco J Pasquel; Guillermo E Umpierrez
Journal:  J Diabetes Sci Technol       Date:  2020-05-05

Review 4.  Preventing all-cause hospitalizations in type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A narrative review and proposed clinical approach.

Authors:  Meir Schechter; Matan Fischer; Ofri Mosenzon
Journal:  Diabetes Obes Metab       Date:  2022-03-24       Impact factor: 6.408

Review 5.  Preparedness cycle to address transitions in diabetes care during the COVID-19 pandemic and future outbreaks.

Authors:  Unjali P Gujral; Leslie Johnson; Jannie Nielsen; Priyathama Vellanki; J Sonya Haw; Georgia M Davis; Mary Beth Weber; Francisco J Pasquel
Journal:  BMJ Open Diabetes Res Care       Date:  2020-07

Review 6.  Blood Glucose Control Strategy for Type 2 Diabetes Patients With COVID-19.

Authors:  Hiroyuki Futatsugi; Masato Iwabu; Miki Okada-Iwabu; Koh Okamoto; Yosuke Amano; Yutaka Morizaki; Takashi Kadowaki; Toshimasa Yamauchi
Journal:  Front Cardiovasc Med       Date:  2020-10-28

Review 7.  Caring for Hospitalized Patients with Diabetes Mellitus, Hyperglycemia, and COVID-19: Bridging the Remaining Knowledge Gaps.

Authors:  Amisha Wallia; Grace Prince; Emilie Touma; Malek El Muayed; Jane Jeffrie Seley
Journal:  Curr Diab Rep       Date:  2020-11-26       Impact factor: 4.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.